NASDAQ:PRAN Alterity Therapeutics (PRAN) Stock Price, News & Analysis → Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad) Free PRAN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.14▼$2.5050-Day Range$0.95▼$2.0652-Week Range$1.09▼$2.91Volume172,845 shsAverage Volume130,956 shsMarket Capitalization$20.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Alterity Therapeutics alerts: Email Address Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Alterity Therapeutics Stock (NASDAQ:PRAN)Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.Read More Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy PRAN Stock News HeadlinesApril 18, 2024 | finance.yahoo.comKazia Therapeutics Limited (KZIA)December 21, 2023 | nasdaq.comAlterity Therapeutics Says Phillip Hains To Replace Kathryn Andrews As CFOApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.December 21, 2023 | markets.businessinsider.comAlterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 4, 2023 | seekingalpha.comAlterity jumps after promising data on Parkinson's candidateDecember 4, 2023 | investorplace.comWhy Is Alterity Therapeutics (ATHE) Stock Up 150% Today?October 31, 2023 | morningstar.comAxsome Therapeutics Inc AXSMOctober 8, 2023 | morningstar.comADRs End Higher; Orchard Therapeutics PLC Climbs 96%April 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.August 23, 2023 | technews.tmcnet.comAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer'sMarch 14, 2023 | technews.tmcnet.comAlterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's DiseaseJanuary 30, 2023 | marketwatch.comAlterity: Study Shows ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal ModelSeptember 26, 2022 | benzinga.comAlterity Therapeutics Stock (OTC:PRNAF), Analyst Ratings, Price Targets, PredictionsSeptember 20, 2022 | msn.comHere's Why Alterity Therapeutics Shares Are VolatileSee More Headlines Receive PRAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRAN CUSIPN/A CIK1131343 Webwww.pranabio.com Phone(139) 349-4906FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick RatioN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales126.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book1.52Miscellaneous Outstanding Shares8,900,000Free FloatN/AMarket Cap$18.96 million OptionableNot Optionable Beta1.05 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesGeoffrey Paul KemplerExecutive Chairman & Chief Executive OfficerKathryn J. E. AndrewsChief Financial OfficerDavid A. StamlerChief Medical Officer & SVP-Clinical DevelopmentPhillip Allen HainsSecretaryKey CompetitorsGalectoNASDAQ:GLTOAlaunos TherapeuticsNASDAQ:TCRTFlora GrowthNASDAQ:FLGCNeuroSense TherapeuticsNASDAQ:NRSNKALA BIONASDAQ:KALAView All Competitors PRAN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA), Conatus Pharmaceuticals (CNAT), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO) and Microbot Medical (MBOT). This page (NASDAQ:PRAN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmithNew York goes dark, then America.Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
